ffects of Zinc-Rich Food Intake Guidance on Prevention of Chemotherapy-Induced Peripheral Neuropathy in Gynecologic Cancer Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1040250065

Enrollment

Registered

2025-07-22

Start date

2025-07-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cance cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer

Interventions

Nutritional counseling on zinc-rich food intake

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Patients who provided written informed consent of their own free will after receiving sufficient explanation and demonstrating adequate understanding of study participation. 2. Patients aged 20 years or older and younger than 75 years at the time of consent. 3. Patients with histologically confirmed primary gynecologic cancer (cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, or primary peritoneal cancer). 4. Patients deemed appropriate candidates for TC (paclitaxel/carboplatin) therapy. 5. Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. 6. Patients with adequate bone marrow function, hepatic function, and renal function.

Exclusion criteria

Exclusion criteria: 1. Patients with pre-existing peripheral neuropathy (CTCAE grade 2 or higher). 2. Patients with a history of prior chemotherapy 3. Patients deemed inappropriate for study participation by the principal investigator or co-investigators

Design outcomes

Primary

Measure	Time frame
Comparison of CIPN incidence and severity changes between control and intervention groups using CTCAE v5.0.	—

Secondary

Measure	Time frame
1. Correlation between serum zinc levels and incidence and severity of CIPN. 2. Comparison of changes in CIPN incidence and severity between control and intervention groups using the Japanese version of FACT/GOG-NTx questionnaire. 3. Incidence and severity of CIPN during TC therapy. 4. Changes in serum zinc levels compared to baseline. 5. Progression-Free Survival (PFS) 6. Response Rate (RR)	—

Contacts

Public ContactYutaka Torii

Fujita Health University Okazaki Medical Center

y-torii@fujita-hu.ac.jp+81-564-64-8800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026